Table 1 Parameter values
Parameter | Minimum | Maximum | Source |
|---|---|---|---|
Disease-free to undetected local recurrence (5Â year probability) | 0.15 | 0.3 | Guadagnolo et al. [34] |
Disease-free to undetected oligometastasis (5Â year probability) | 0.3 | 0.45 | Guadagnolo et al. [34] |
Undetected to clinically detected local recurrence (1Â year probability) | 0.6 | 0.9 | Expert opinion |
Undetected to clinically detected oligometastasis (1Â year probability) | 0.5 | 0.8 | Expert opinion |
Undetected local recurrence to oligometastasis (1Â year probability) | 0.12 | 0.2 | Expert opinion (based on detected local recurrence parameter values) |
Clinically detected local recurrence to oligometastasis (1Â year probability) | 0.075 | 0.12 | Daigeler et al. [35]; Guadagnolo et al. [34]; Whooley et al. [28] |
Image detected local recurrence to oligometastasis (1Â year probability) | 0.075 | 0.12 | Daigeler et al. [35]; Guadagnolo et al. [34]; Whooley et al. [28] |
Undetected oligometastasis to polymetastases (1Â year probability) | 0.4 | 0.6 | Expert opinion (based on detected oligometastases parameter values) |
Detected oligometastasis to polymetastasis (1Â year probability) | 0.2 | 0.3 | Welter et al. [36] |
Polymetastasis to sarcoma-related death (1Â year probability) | 0.2 | 0.3 | |
CT sensitivity | 0.95 | 1 | Christie-Large et al. [37] |
CT specificity | 0.9 | 1 | Christie-Large et al. [37] |
MRI sensitivity | 0.87 | 1 | Park et al. [38] |
MRI specificity | 0.65 | 0.79 | Park et al. [38] |
PET sensitivity | 0.82 | 1 | Bastiaannet et al. [39] |
PET specificity | 0.77 | 0.94 | Bastiaannet et al. [39] |
Proportion with metastatic disease at 5 years | 0.25 | 0.32 | Sarculator® |
Proportion with metastatic disease at 10 years | 0.28 | 0.36 | Sarculator® |
Mortality at 5 years | 0.23 | 0.30 | Sarculator® |
Mortality at 10 years | 0.32 | 0.40 | Sarculator® |